The role of lipoprotein(a) in atherogenesis and thrombosis

Annual Review of Medicine

Volumn 47, Issue , 1996, Pages 423-442

  Hajjar, Katherine A ^a   Nachman, Ralph L ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Fibrinolysis; Growth factors; Lipid metabolism; Polymorphism; Vascular biology

Indexed keywords

ACETYLCYSTEINE; APOLIPOPROTEIN A; CELL SURFACE RECEPTOR; CHOLESTEROL; ENZYME PRECURSOR; FIBRIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLASMIN; PLASMINOGEN; SERINE PROTEINASE;

APHERESIS; ATHEROGENESIS; ATHEROSCLEROSIS; CELL PROLIFERATION; FIBRINOLYSIS; HUMAN; HYPERLIPOPROTEINEMIA; KRINGLE DOMAIN; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS; VASCULAR SMOOTH MUSCLE;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPROTEIN(A); MUSCLE, SMOOTH, VASCULAR; THROMBOSIS;

EID: 0029964212     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.47.1.423     Document Type: Review

References (137)

1. Berg K. 1963. A new serum type system in man - the Lp system. Acta Pathol. Microbiol. Scand. 59:369-82
2. Walton KW, Hitchens J, Magnani HN, et al. 1974. A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis 20: 323-46
3. Dahlen G, Berg K, Gillnas T, et al. 1975. Lp(a) lipoprotein/pre-beta-lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin. Genet. 7:334-41
4. Kostner GM, Avogaro P, Cazzolato G, et al. 1981. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38: 51-61
5. Armstrong VW, Cremer P, Eberle E, et al. 1986. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis 62:249-57
6. Dahlen GH, Guyton JR, Attar M, et al. 1986. Association of levels of lipoprotein(a) Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 74: 758-65
7. Rhoads GG, Dahlen G, Berg K, et al. 1986. Lp(a) lipoprotein is a risk factor for myocardial infarction. JAMA 256:2540-44
8. Durrington PN, Ishola M, Hunt L, et al. 1988. Apolipoprotein(a), A1, and B and parental history in men with early onset ischaemic heart disease. Lancet 1: 1070-73
9. Shintani S, Kikuchi S, Hamaguchi H, et al. 1993. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 24:965-69
10. Fless GM, Rolih CA, Scanu AM. 1984. Heterogeneity of human plasma lipoprotein(a): isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol. Chem. 259:11470-78
11. Sommer A, Gorges R, Kostner GM, et al. 1991. Sulhydryl-selective fluorescence labeling of lipoprotein(a) reveals evidence for one single disulfide linkage between apoprotein(a) and B-100. Biochemistry 30: 11245-49
12. Fless GM, ZumMallen ME, Scanu AM. 1985. Isolation of apolipoprotein(a) from lipoprotein(a). J. Lipid Res. 26:1224-29
13. Gaubatz JM, Heideman C, Gotto AM, et al. 1983. Human plasma lipoprotein(a) structural properties. J. Biol. Chem. 258: 4582-89
14. Hess GM, ZumMallen ME, Scanu AM. 1986. Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein(a). J. Biol. Chem. 261: 8712-18
15. Koschinsky ML, Beisiegel U, Henne-Bruns D, et al. 1990. Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochemistry 29:640-44
16. Utermann G, Menzel HJ, Kraft HG, et al. 1987. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J. Clin. Invest. 80:458-65
17. Eaton DL, Fless GM, Kohr WJ, et al. 1987. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc. Natl. Acad. Sci. USA 84: 3224-28
18. McLean JW, Tomlinson JE, Kuang WJ, et al. 1987. cDNA sequence of human apolipoprotein is homologous to plasminogen. Nature 330:132-37
19. Weitkamp LK, Guttormsen SA, Schultz JS. 1988. Linkage between the loci for the Lp(a) lipoprotein and plasminogen. Hum. Genet. 79:80-82
20. Frank SL, Klisak I, Sparkes RS, et al. 1988. The apolipoprolein(a) gene resides on human chromosome 6q26-27, in close proximity to the homologous gene for plasminogen. Hum. Genet. 79:352-56
21. Byrne CD, Schwartz K, Meer K, et al. 1994. The human apolipoprotein(a)/plasminogen gene cluster contains a novel homologue transcribed in liver. Arterioscler. Thromb. 14:534-41
22. Ichinose A. 1992. Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. Biochemistry 31:3113-18
23. Frank SL, Klisak I, Sparkes RS, et al. 1989. A gene homologous to plasminogen located on human chromosome 2q11-p11. Genomics 4:449-51
24. Vali Z, Patthy L. 1982. Location of the intermediate and high affinity omega-aminocarboxylic acids-binding sites in human plasminogen. J. Biol. Chem. 257:2104-10
25. Plow EF, Collen D. 1981. Immunochemical characterization of a low affinity lysine binding site within plasminogen. J. Biol. Chem. 256:10864-69
26. Cole KR, Castellino FJ. 1984. The binding of antifibrinolytic amino acids to kringle-4-containing fragments of plasminogen. Arch. Biochem. Biophys. 229:568-75
27. Tulinsky A, Park CH, Mao B, et al. 1988. Lysine/fibrin binding sites of kringles modeled after the structure of kringle I of prothrombin. Proteins 3:85-86
28. 37. J. Clin. Invest. 91:283-91
29. Armstrong VW, Harrach B, Robenek H, et al. 1990. Heterogeneity of human lipoprotein(a): cytochemical and biochemical studies on the interaction of two species with the LDL receptor. J. Lipid Res. 31: 429-41
30. Hervio L, Chapman MJ, Thillet J, et al. 1993. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 82:392-97
31. Gaw A, Hobbs HH. 1994. Molecular genetics of lipoprotein(a): new pieces to the puzzle. Curr. Opin. Lipidol. 5:149-55
32. Rader DJ, Cain W, Ikewaki K, et al. 1994. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J. Clin. Invest. 93:2758-63
33. Gavish D, Azrolan N, Breslow JL. 1989. Plasma Lp(a) concentration is inversely correlated with the ratio of kringle IV/Kringle V encoding domains in the apo(a) gene. J. Clin. Invest. 84:2021-27
34. Azrolan N, Gavish D, Breslow JL. 1991. Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model. J. Biol. Chem. 266:13866-72
35. Lackner C, Boerwinkle E, Leffert CC, et al. 1991. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis. J. Clin. Invest. 87:2153-61
36. Cohen JC, Chiesa G, Hobbs HH. 1993. Sequence polymorphisms in the apolipoprotein(a) gene: evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels. J. Clin. Invest. 91: 1630-36
37. Perombelon YFN, Soutar AK, Knight BL. 1994. Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles. J. Clin. Invest. 93: 1481-92
38. Malgretti N, Acquati F, Magnaghi P, et al. 1992. Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5′ flanking region. Proc. Natl. Acad. Sci. USA 89:11584-88
39. Wade DP, Clarke JG, Lindahl GE, et al. 1993. 5′ Control regions of the apolipoprotein(a) gene and members of the related plasminogen gene family. Proc. Natl. Acad. Sci. USA 90:1369-73
40. Wade DP, Lindahl GE, Lawn RM. 1994. Apolipoprotein(a) gene transcription is regulated by liver-enriched trans-acting factor hepatocyte nuclear factor Ia. J. Biol. Chem. 269:19757-65
41. Maeda S, Abe A, Seishima M, et al. 1989. Transient changes in serum lipoprotein(a) as an acute phase protein. Atherosclerosis 78:145-50
42. Ichinose A, Kuriyama M. 1995. Detection of polymorphisms in the 5′-flanking region of the gene for apolipoprotein(a). Biochem. Biophys. Res. Commun. 209:372-78
43. Trommsdorff M, Kochl S, Lingenhel A, et al. 1995. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians. J. Clin. Invest. 96:150-57
44. Zysow BR, Lindahl GE, Wade DP, et al. 1995. C/T polymorphism in the 5′ untranslated region of the apolipoprotein(a) gene introduces an upstream ATG and reduces in vitro translation. Arterioscler. Thromb. 15: 58-64
45. Utermann G. 1989. The mysteries of lipoprotein(a). Science 246:904-10
46. Liu AC, Lawn RM. 1994. Lipoprotein(a) and atherogenesis. Trends Cardiovasc. Med. 4:40-44
47. Budde T, Fechtrup C, Bosenberg E, et al. 1994. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler. Thromb. 14:1730-36
48. Sandkamp M, Funke H, Schulte H, et al. 1990. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin. Chem. 36/1:20-23
49. Moliterno DJ, Lange RA, Meidell RS, et al. 1993. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation 88:935-40
50. Hoff HF, Bech GJ, Skibinski CI, et al. 1988. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 77: 1238-44
51. Cushing GL, Gaubatz JW, Nava ML, et al. 1989. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 9:593-603
52. Pepin JM, O'Neil JA, Hoff HA. 1991. Quantification of apo(a) and apoB in human atherosclerotic lesions. J. Lipid Res. 32:317-27
53. Rath M, Nienhorf A, Reblin T, et al. 1989. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9:579-92
54. Barbir M, Kushwaha S, Hart B, et al. 1992. Lipoprotein(a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet 340:1500-1
55. Zenker G, Koltringer P, Bone G, et al. 1986. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 17:942-45
56. Shintani S, Kikuchi S, Hamaguchi H, et al. 1993. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke. 24:965-69
57. Hajjar KA, Gavish D, Breslow JL, et al. 1989. Lipoprotein(a) modulates endothelial cell surface fibrinolysis: potential role in atherosclerosis. Nature 339:303-5
58. Floren C-H, Albers JJ, Bierman EL. 1981. Uptake of Lp(a) by cultured fibroblasts. Biochem. Biophys. Res. Commun. 102: 636-39
59. Krempler F, Kostner GM, Roscher A, et al. 1983. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J. Clin. Invest. 71:1431-41
60. Snyder ML, Polacek D, Scanu AM, et al. 1992. Comparative binding and degradation of lipoprotein(a) and low density lipoprotein by human monocyte-derived macrophages. J. Biol. Chem. 267:339-46
61. Zioncheck TF, Powell LM, Rice GC, et al. 1991. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J. Clin. Invest. 87:767-71
62. Hofmann SL, Eaton DL, Brown MS, et al. 1990. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) in transgenic mice. J. Clin. Invest. 85:1542-47
63. De Rijke YB, Jurgens G, Hessels EMAJ, et al. 1992. In vivo fate and scavenger receptor recognition of oxidized lipoprotein(a) isoforms in rats. J. Lipid Res. 33: 1315-25
64. Haberland ME, Fless GM, Scanu AM, et al. 1992. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J. Biol. Chem. 267:4143-51
65. Naruszewicze M, Gusoux LM, Davigion J. 1994. Oxidative modification of Lp(a) causes changes in the structure and biological properties of apo(a). Chem. Phys. Lipids 67:167-74
66. Keesler GA, Li Y, Skiba PJ, et al. 1994. Macrophage foam cell lipoprotein(a)/apoprotein(a) receptor. Arterioscler. Thromb. 14:1337-45
67. Lawn R, Wade D, Hammer R, et al. 1992. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360: 670-72
68. Kostner GM, Grillhofer HK. 1991. Lipoprotein(a) mediates high affinity low density lipoprotein association to receptor negative fibroblasts. J. Biol. Chem. 166: 21287-92
69. Bottalico LA, Keesler GA, Fless GM, et al. 1993. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J. Biol. Chem. 268: 8569-73
70. Ross R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-9
71. Salonen E-M, Jauhiainen M, Zardi L, et al. 1989. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J. 8:4035-40
72. Karadi I, Kostner GM, Gries A, et al. 1988. Lipoprotein(a) and plasminogen are immunochemically related. Biochim. Biophys. Acta 960:91-97
73. Edelberg JM, Gonzales-Gronow M, Pizzo SV. 1989. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 28:2370-74
74. Simon DI, Fless GM, Scanu AM, et al. 1991. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry 30:6671-77
75. Loscalzo J, Weinfeld M, Fless GM, et al. 1990. Lipoprotein(a), fibrin binding and plasminogen activation. Arteriosclerosis 10:240-45
76. Harpel PC, Gordon BR, Parker TS. 1989. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc. Natl. Acad. Sci. USA 56:3847-51
77. Harpel PC, Chang VT, Borth W. 1992. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc. Natl. Acad. Sci. USA 89:10193-97
78. Palabrica TM, Liu AC, Aronovitz MJ, et al. 1995. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature 1:256-59
79. Hajjar KA. 1995. Cellular receptors in the control of fibrinolysis. Thromb. Haemostasis 74:213-17
80. Miles LA, Dahlberg CM, Levin EG, et al. 1990. Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these components to cells. Biochemistry 193:759-65
81. Miles LA, Dahlberg CM, Plescia J, et al. 1991. Role of cell-surface lysines in plasminogen binding to cells: identification of α-enolase as a candidate plasminogen receptor. Biochemistry 30:1682-91
82. Kanalas JJ, Makker SP. 1991. Identification of the rat Heymann nephritis autoantigen (GP330) as a receptor site for plasminogen. J. Biol. Chem. 266:10825-29
83. Lottenberg R, Broder CC, Boyle MDP, et al. 1992. Cloning, sequence analysis, and expression in Escherichia coli of a streptococcal plasmin receptor. J Bacteriol. 174: 5204-10
84. Miles LA, Ginsberg MH, Plow EF. 1986. Plasminogen interacts with human platelets through two distinct mechanisms. J. Clin. Invest. 77:2001-9
85. Gonzales-Gronow M, Gawdi G, Pizzo SV. 1994. Characterization of the plasminogen receptors of normal and rheumatoid arthritis human synovial fibroblasts. J. Biol. Chem. 269:4360-66
86. Parkkinen J, Rauvala H. 1991. Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin: enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J. Biol. Chem. 266: 16730-35
87. Hajjar KA, Jacovina AT, Chacko J. 1994. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem. 269: 21191-97
88. Raynal P, Pollard HB. 1994. Annexins: the problem of assessing the biologic role for a gene family of multifunctional calcium-and phospholipid-binding proteins. Biochim. Biophvs. Acta. 1197:63-93
89. Swairjo MA, Seaton BA. 1994. Annexin structure and membrane interactions: a molecular perspective. Annu. Rev. Biophys. Biomol. Struct. 23:193-213
90. Wright JF, Kurosky A, Wasi S. 1994. An endothelial cell-surface form of annexin II binds human cytomegalovirus. Biochem. Biophys. Res. Commun. 198:983-89
91. Chung CY, Erickson HP. 1994. Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J. Cell Biol. 126:539-48
92. v-src and of the epidermal growth factor receptor/kinase. Cell 46:191-99
93. Hajjar KA, Hamel NM. 1990. Identification and characterization of human endothelial cell binding sites for tissue plasminogen activator and urokinase. J. Biol. Chem. 265:2908-16
94. Hajjar KA. 1991. The endothelial cell tissue plasminogen activator receptor: specific interaction with plasminogen. J. Biol. Chem. 266:21962-70
95. Hajjar KA, Harpel PC, Jaffe EA, et al. 1986. Binding of plasminogen to cultured human endothelial cells. J. Biol. Chem. 261:11656-62
96. Hajjar KA, Nachman RL. 1988. Endothelial cell mediated conversion of glu-plasminogen to lys-plasminogen. Further evidence for assembly of fibrinolytic proteins on endothelial cells. J. Clin. Invest. 82: 1769-78
97. Hajjar KA. 1993. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell receptor. J. Clin. Invest. 91:2873-79
98. Miles LA, Fless GM, Levin EG, et al. 1989. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 339: 301-3
99. Gonzalez-Gronow M, Edelberg JM, Pizzo SV. 1989. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry 28: 2374-77
100. Ezratty A, Simon DI, Loscalzo J. 1993. Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 32:4628-33
101. Hajjar KA, Hamel NM, Harpel PC, et al. 1987. Binding of tissue plasminogen activator to cultured human endothelial cells. J. Clin. Invest. 80:1712-19
102. Cesarman GM, Guevara CA, Hajjar KA. 1994. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA) II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol Chem. 269:21198-203
103. Kojima S, Harpel PC, Rifkin DB. 1991. Lipoprotein(a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J. Cell Biol. 113:1439-45
104. Lyons RM, Gentry LE, Purchio AF, et al. 1990. Mechanism of latent recombinant transforming growth factor β1 by plasmin. J. Cell Biol. 110:1361-67
105. Sato Y, Rifkin DB. 1989. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J. Cell Biol. 109:309-15
106. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. 1993. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 260:1655-58
107. Grainger DJ, Kemp PR, Liu AC, et al. 1994. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 370:460-42
108. Petersen TE, Martzen MR, Ichinose A, et al. 1990. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J. Biol. Chem. 265: 6104-11
109. Ichinose A, Espling ES, Takamatso J, et al. 1991. Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. Proc. Natl. Acad. Sci. USA 88:115-19
110. Forsgren M, Raden B, Israelsson M, et al. 1987. Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett. 213: 254-60
111. Weissbach L, Treadwell BV. 1992. A plasminogen-related gene is expressed in cancer cells. Biochem. Biophys. Res. Commun. 186:1108-14
112. Nakamura T, Nishizawa T, Hagiya M, et al. 1989. Molecular cloning and expression of human hepatocyte growth factor. Nature 342:440-43
113. Han S, Stuart LA, Degen SJF. 1991. Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry 30:9768-80
114. Yoshimura T, Yuhki N, Wang M-H, et al. 1993. Cloning, sequencing, and expression of human macrophage stimulating protein (MSP, MST 1) confirms MSP as a member of the family of kringle proteins and locates the MSP gene on chromosome 3. J. Biol. Chem. 268:15461-68
115. Morimoto A, Tada K, Nakayama Y, et al. 1994. Cooperative roles of hepatocyte growth factor and plasminogen activator in tubular morphogenesis by human microvascular endothelial cells. Jpn. J. Cancer Res. 85:53-62
116. Morimoto A, Okamura K, Hamanaka R, et al. 1991. Hepatocyte growth factor modulates migration and proliferation of human smooth microvascular endothelial cells. Biochem. Biophvs. Res. Commun. 179: 1042-49
117. Bussolino F, DiRenzo MF, Ziche M, et al. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motllily and growth. J. Cell Biol. 119:629-41
118. O'Reilly MS, Holmgren L, Shing Y, et al. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-28
119. Barger AC, Beeuwkes R, Lairey L, et al. 1984. Hypothesis: vasa vasorum and neovascularization of human coronary arteries: a possible role in the pathogenesis of atherosclerosis. N. Engl. J. Med. 310: 175-77
120. O'Brien ER, Garvin MR, Dev R, et al. 1994. Angiogenesis in human coronary atherosclerotic plaques. Am. J. Pathol. 145: 883-94
121. Schneiderman J, Bordin GM, Engelberg I, et al. 1995. Expression of fibrinolytic genes in atherosclerotic abdominal aortic aneurysm wall: a possible mechanism for aneurysm expansion. J. Clin. Invest. 96: 639-45
122. Nachman RL. 1992. Thrombosis and ather ogenesis: molecular connections. Blood 79:1897-906
123. Meekins JW, Pijnenborg R, Harssens M, et al. 1994. Immunohistochemical detection of lipoprotein(a) in the wall of placental bed, spiral arteries in normal and severe preeclamptic pregnancies. Placenta 15: 511-24
124. Takami S, Kihara S, Yomoshita S, et al. 1994. Enhanced expression of intercellular adhesion molecule-1 (ICAM-1) in human umbilical vein endothelial cells (HUVEC) by lipoprotein(a). Circulation 90:1-623 (Abstr.)
125. Sorensen KE, Celermayer DS, Georgakopoulos D, et al. 1994. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J. Clin. Invest. 93:50-55
126. Thompson WD, Smith EB. 1989. Atherosclerosis and the coagulation system. J. Pathol. 159:97-106
127. Etingin OR, Hajjar DP, Hajjar KA, et al. 1991. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol. Chem. 266:2459-65
128. Fless GA, Snyder ML, Scanu AM. 1989. Enzyme-linked immunoassay for Lp(a). J. Lipid. Res. 30:651-62
129. Scanu AM. 1992. Lipoprotein(a): a genetic risk factor for premature coronary heart disease. JAMA 267:3326-29
130. Gavish D, Breslow JL. 1991. Lipoprotein(a) reduction by N-acetylcysteine. Lancet 337:203-4
131. Carlson LA, Hamsten A, Asplund A. 1989. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J. Int. Med. 226:271-76
132. Seed M, O'Connor B, Perombolon N, et al. 1993. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 101:61-68
133. Armstrong VW, Schleef J, Thiery J, et al. 1989. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur. J. Clin. Invest. 19:235-40
134. Armstrong VW, Schuff-Werner P, Eisenhauer T, et al. 1994. Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chem. Phys. Lipids 67/68:315-21
135. Brown MS, Goldstein JL. 1989. Teaching old dogmas new tricks. Nature 330:113-14
136. Tomlinson JE, McLean JW, Lawn RM. 1989. Rhesus monkey apolipoprotein(a). J. Biol. Chem. 264:5957-65
137. Laplaud PM, Beaubatie L, Rail SC, et al. 1988. Lipoprotein(a) is the major apo B-containing lipoprotein in the plasma of a hibernator hedgehog (Erinaceus europeus). J. Lipid Res. 29:1157-70